Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CODXNASDAQ:CTCXNASDAQ:PAVMNASDAQ:PETV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCODXCo-Diagnostics$0.27-1.7%$0.32$0.23▼$2.23$9.10M0.57237,608 shs202,381 shsCTCXCarmell$2.60-1.5%$1.44$0.17▼$2.06$54.35M0.514.01 million shs23,813 shsPAVMPAVmed$0.63-2.1%$0.68$0.55▼$1.90$10.69M1.06131,416 shs93,694 shsPETVPetVivo$0.70-1.1%$0.67$0.29▼$0.98$16.99M0.8720,462 shs15,529 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCODXCo-Diagnostics-1.74%-9.09%-9.67%-38.55%-82.96%CTCXCarmell0.00%-4.76%-13.33%+1,030.43%+30.65%PAVMPAVmed-2.08%-2.65%-3.67%-18.41%-41.02%PETVPetVivo-1.13%-6.67%-8.97%+27.27%+19.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCODXCo-Diagnostics4.1531 of 5 stars3.53.00.04.42.50.01.3CTCXCarmellN/AN/AN/AN/AN/AN/AN/AN/APAVMPAVmed3.8517 of 5 stars3.53.00.04.32.00.00.6PETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCODXCo-Diagnostics 3.00Buy$5.501,929.52% UpsideCTCXCarmell 0.00N/AN/AN/APAVMPAVmed 3.00Buy$19.002,939.03% UpsidePETVPetVivo 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CTCX, PETV, CODX, and PAVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.50 ➝ $19.004/28/2025CODXCo-DiagnosticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025CODXCo-DiagnosticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.004/21/2025PAVMPAVmedAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $19.503/28/2025CODXCo-DiagnosticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$1.50 ➝ $1.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCODXCo-Diagnostics$3.71M2.45N/AN/A$2.81 per share0.10CTCXCarmell$32.84K1,655.14N/AN/A$1.07 per share2.43PAVMPAVmed$1.99M5.36N/AN/A($3.35) per share-0.19PETVPetVivo$1.05M16.24N/AN/A($0.03) per share-23.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCODXCo-Diagnostics-$35.33M-$1.17N/AN/AN/A-563.93%-54.94%-49.28%8/6/2025 (Estimated)CTCXCarmell-$15.44MN/A0.00∞N/AN/A-217.50%-50.22%N/APAVMPAVmed-$64.18M$0.71N/AN/AN/A602.97%N/A-92.36%8/12/2025 (Estimated)PETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%6/26/2025 (Estimated)Latest CTCX, PETV, CODX, and PAVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CODXCo-Diagnostics-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 million3/27/2025Q4 2024CODXCo-Diagnostics-$0.34-$0.36-$0.02-$0.36$0.38 million$0.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCODXCo-DiagnosticsN/AN/AN/AN/AN/ACTCXCarmellN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCODXCo-DiagnosticsN/A6.926.70CTCXCarmellN/A0.310.29PAVMPAVmedN/A0.060.06PETVPetVivo0.020.420.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCODXCo-Diagnostics14.99%CTCXCarmell24.22%PAVMPAVmed19.93%PETVPetVivo24.55%Insider OwnershipCompanyInsider OwnershipCODXCo-Diagnostics8.40%CTCXCarmell29.00%PAVMPAVmed7.30%PETVPetVivo10.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCODXCo-Diagnostics10033.57 million29.98 millionOptionableCTCXCarmell1420.91 million14.84 millionNot OptionablePAVMPAVmed9017.09 million9.82 millionOptionablePETVPetVivo2024.27 million19.06 millionNot OptionableCTCX, PETV, CODX, and PAVM HeadlinesRecent News About These CompaniesPetVivo Holdings Secures $200K in Equity FinancingJune 16 at 4:23 PM | tipranks.comCritical Survey: PetVivo (NASDAQ:PETV) vs. T2 Biosystems (NASDAQ:TTOO)June 8, 2025 | americanbankingnews.comNew to The Street Announces Upcoming Bloomberg Air Dates Featuring FLOKI, BioVie Pharmaceuticals, Beeline, Arrive AI, and CommercialvilleJune 7, 2025 | indystar.comPetVivo and Commonwealth Partner to Advance Equine Wellness Across Thoroughbred RacingJune 6, 2025 | globenewswire.comDigital Landia, LLC, in Cooperation with PetVivo Holdings, Inc., Announces Invite-Only MVP Availability Amid Stress-Testing & Debugging PhaseMay 29, 2025 | globenewswire.comPetVivo Holdings Inc (PETV)May 27, 2025 | investing.comPetvivo Holdings, Inc. and PiezoBioMembrane Inc. Announce Master Services Agreement to Jointly Develop Innovative Functional BiomaterialsMay 22, 2025 | globenewswire.comDIGITAL LANDIA, LLC IN COOPERATION WITH PETVIVO HOLDINGS, INC. UNVEILS REVOLUTIONARY AUTONOMOUS PET AI ECOSYSTEM TRANSFORMING PET CARE WITH SELF-LEARNING MULTI-AGENT AI TECHNOLOGYMay 13, 2025 | globenewswire.comPetVivo Holdings, Inc. Announces Participation in the D. Boral Capital Inaugural Global ConferenceMay 2, 2025 | newsfilecorp.comPETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH EQ ESPECIALIDADESApril 16, 2025 | globenewswire.comPetVivo closes Series B Convertible Preferred Stock offeringApril 2, 2025 | markets.businessinsider.comPETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF SERIES B CONVERTIBLE PREFERRED STOCK OFFERINGMarch 31, 2025 | globenewswire.comPetVivo, Digital Landia announce partnership for Agentic AI solutionsMarch 3, 2025 | markets.businessinsider.comPetvivo Holdings, Inc. and Digital Landia Corp. Announce Groundbreaking Strategic Alliance Agreement to Pioneer Agentic AI for Animal CommunicationMarch 3, 2025 | globenewswire.comPetVivo Holdings Renames Subsidiary to Focus on Animal HealthFebruary 28, 2025 | tipranks.comPetvivo Holdings, Inc. to Exhibit at the Western Veterinary Conference in Las Vegas, NevadaFebruary 19, 2025 | globenewswire.comPetVivo Holdings, Inc.: PetVivo Reports Fiscal Q3 2025 ResultsFebruary 15, 2025 | finanznachrichten.dePetVivo signs exclusive sales, marketing agreement with VetStemFebruary 14, 2025 | markets.businessinsider.comEarnings call transcript: PetVivo Q3 2025 highlights revenue surgeFebruary 14, 2025 | msn.comPetVivo Reports Fiscal Q3 2025 ResultsFebruary 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTCX, PETV, CODX, and PAVM Company DescriptionsCo-Diagnostics NASDAQ:CODX$0.27 0.00 (-1.74%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.29 +0.02 (+5.54%) As of 06/16/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Carmell NASDAQ:CTCX$2.60 -0.04 (-1.52%) As of 06/13/2025Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.PAVmed NASDAQ:PAVM$0.63 -0.01 (-2.08%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$0.62 -0.01 (-0.83%) As of 06/16/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.PetVivo NASDAQ:PETV$0.70 -0.01 (-1.13%) As of 06/16/2025 03:15 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
